But given the growth, cash flow — LGND is currently positive — and earning’s potential at Ligand, that valuation is really darn cheap. With this biotech stock, you really are getting a glimpse at the next Amgen or Celgene before it happens.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LGND at https://www.zacks.com/ap/LGND
Corbus' common stock was uplisted to the NASDAQ Capital Market from the ... Ligand Pharmaceuticals Inc.'s (LGND) phase Ib clinical trial with investigational diabetes drug LGD-6972 at dosages of 5mg, 10mg and 15mg has …
The stock decreased 0.36% or $0.25 during the last trading session ... It also reduced its holding in Ligand …
The stock closed at $64.89 on Monday. Shares fell more than 4.1 percent to $62.21 after-hours. In pre-market trading, …